Pharmaceutical Technology

MARCH 23, 2023

Scientific research and a better understanding of the condition is driving new developments in medications. The condition’s symptoms are not homogeneous, and that makes drug development complicated,” Javier Szwarcberg, CEO of Spruce Biosciences, a rare disease company researching endocrine disorders, says.

Development 130

Development Insulin Hormones Research 130

pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition. The post Sanofi snaps up acne vaccine developer Origimm Bio appeared first on.

Vaccination 92

Vaccination Vaccine Development Hormones 92

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is administered as an intravenous infusion.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Pharmaceutical Technology

JANUARY 22, 2023

“[In] the last 20 years, there have been a large number of companies that have jumped into the rare disease arena, and for some diseases like Rett syndrome, they have targeted resources to developing therapeutic agents,” he says. T3 is a major hormone in the blood that regulates thyroid levels. In clinical trials, the drug showed a 3.8-point

Drugs 317

Drugs Gene Hormones Clinical Trials 317

The Pharma Data

FEBRUARY 1, 2021

While multiple factors are at play, Mosconi said, it’s hormones – testosterone in men and estrogen in women – that are the orchestral conductors of the brain. “We are used to thinking of sex hormones as important for fertility and reproduction,” Mosconi said. They are responsible for whether it performs well, or not.

Hormones 40

Hormones Radiology Research Medicine 40

XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Hormones 115

Hormones Genetics Genome Genomics 115

XTalks

SEPTEMBER 17, 2020

In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. Acromegaly. Prevalence: 50 to 70 people per 1 million.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Lerner researchers developed a novel artificial intelligence platform to identify potential drugs for COVID-19, finding melatonin to be a promising candidate.

Research 98

Research Hormones Protein Regulation 98

Drug Discovery World

DECEMBER 19, 2023

Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the only treatment. Lack of scientific advancement Before menopause, there is a balance between oestrogen, and the protein neurokinin B (NKB), which regulates the brain’s temperature control centre.

Hormones 59

Hormones Clinical Trials Clinical Trials Medicine 59

XTalks

AUGUST 10, 2022

The drug is being jointly developed and commercialized by AstraZeneca and Japan’s Daiichi Sankyo. HER2-low is characterized by the presence of some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. Enhertu Trial Data. Of the trial participants, females made up 99.6 percent of the group.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

Drug Discovery World

FEBRUARY 21, 2023

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.

HR 52

HR Hormones Sales Antibody 52

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. CDK4/6 inhibitors are used alongside hormone therapy. Rosenberg, M.D.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Drug Discovery World

AUGUST 16, 2023

.” The findings suggest it might be possible to predict who will benefit from carboplatin and docetaxel using a range of different biomarkers and suggest further investigation of these biomarkers in clinical trials is warranted.

Genetics 52

Genetics Gene Hormones RNA 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA Now Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Hormones 52

Hormones HR Trials Protein 52

Pharmaceutical Technology

APRIL 24, 2023

“Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

MARCH 13, 2024

Biomarker testing is being pursued to identify biological signs of the disease and provide an approach to develop personalized treatment plans for each patient. As this technology continues to evolve, it is expected to help identify glaucoma in its nascent stages of development.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

Drug Discovery World

JUNE 6, 2023

Approved treatment options available for patients with advanced LGSOC in the UK are currently limited to chemotherapy and hormone therapy, with response rates typically ranging from 0-14%. Avutometinib is a dual RAF and MEK inhibitor, which blocks certain proteins that help control cancer growth and survival.

Drugs 52

Drugs Research Hormones Trials 52

The Pharma Data

APRIL 7, 2023

2-5 Philipp Harter, Director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: “DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer.

Trials 40

Trials DNA Medicine Development 40

Drug Discovery World

AUGUST 21, 2023

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. However, because these cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs, current treatment options are limited.

Protein 52

Protein Trials Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

AUGUST 31, 2022

Triple-negative breast cancer is invasive breast cancer that does not respond to hormonal therapy medicines or the current medicines that target the HER2 protein. It is usually more aggressive, harder to treat, and more likely to recur than cancers that are hormone receptor-positive or HER2-positive.

Hormones 52

Hormones Doctors Doctor Clinical Trials 52

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

Drug Discovery World

AUGUST 21, 2023

Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity, as shown in the SELECT trial. GLP-1 is a hormone that is produced naturally in the brain and the gut in response to food ingestion.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?

HR 52

HR Hormones FDA Approval Antibody 52

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

SEPTEMBER 28, 2021

Recommendation supported Data From Phase 3 KEYNOTE-355 Trial. Merck is rapidly advancing a broad portfolio in gynecologic and breast cancers through an in depth clinical development program for KEYTRUDA and a number of other other investigational and approved medicines across these areas. About Triple-Negative carcinoma.

Hormones 52

Hormones Medicine Clinical Research Research 52

The Pharma Data

SEPTEMBER 10, 2021

Senior Vice President, Chief Development Officer, Internal Medicine and Hospital, Global Product Development at Pfizer. “We Myovant and Pfizer are jointly developing and commercializing MYFEMBREE in the U.S. Hormone-Sensitive Malignancies: Discontinue MYFEMBREE if a hormone-sensitive malignancy is diagnosed.

Hormones 52

Hormones FDA Approval Drugs Development 52

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. It works by targeting a protein called B-lymphocyte stimulator (BLyS) that is overproduced in people with lupus and contributes to an overactive immune system.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

Roots Analysis

AUGUST 31, 2023

Further, the expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. There are various regulatory proteins or transcription factors that are responsible for affecting the transcription rate. When activator binds to the operon, it either speeds up or permits gene expression.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

APRIL 27, 2022

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. For more information about the trial, visit ClinicalTrials.gov. Enhertu Enhertu is a HER2-directed ADC.

HR 52

HR Trials Protein Medicine 52

Delveinsight

DECEMBER 7, 2020

For instance, the shortage of healthcare professionals can be tackled by creating better diagnostic and treatment procedures, integrating solutions developed by physicians worldwide, and providing them seamlessly over a platform accessed by all practicing physicians. In May 2018, Ava raised about $30 million in a Series B round.

Protein 56

Protein Insulin Hormones FDA Approval 56

Drug Discovery World

JANUARY 9, 2024

Budesonide (Tarpeyo/Kinpeygo/Nefecon), Calliditas Therapeutics, Everest Medicines and STADA Arzneimittel Tarpeyo/Kinpeygo (developed under the project name Nefecon) is a second-generation, synthetic, non-halogenated form of the corticosteroid budesonide. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

Delveinsight

JANUARY 7, 2021

Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

XTalks

FEBRUARY 5, 2024

This article serves as a resource for healthcare professionals, life sciences researchers and industry enthusiasts seeking to stay informed of the latest developments and success stories in oncology therapeutics. Darzalex (Daratumumab) Darzalex 2022 Sales: $7.977 billion Company/Developer: Janssen Biotech, Inc.,

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

MARCH 22, 2021

VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021. More than 15 dedicated early to late development and research programs underway to identify the next wave of radioligand therapies for cancer. About Advanced Prostate Cancer.

Hormones 52

Hormones Gene Therapy Trials Medicine 52

Drug Discovery World

APRIL 11, 2024

On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development. LAE119 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper.

HR 52

HR Antibody In-Vitro DNA 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. 1. -- -->. -- [if lte IE 8]--> . Iksuda Therapeutics – U.K.-based

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52